Seoul Pharma Co., Ltd (KOSDAQ:018680)
South Korea flag South Korea · Delayed Price · Currency is KRW
1,991.00
-24.00 (-1.19%)
At close: Jul 31, 2026

Seoul Pharma Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
725.89753.641,6993,517855.09-9,689
Depreciation & Amortization
2,6632,6622,4901,9282,6132,528
Loss (Gain) From Sale of Assets
1.781.780.058.260.020.01
Asset Writedown & Restructuring Costs
----2,177198.8
Loss (Gain) From Sale of Investments
---67.49-63.71--
Provision & Write-off of Bad Debts
17.2324.64-14.53-6.14-9.6424.12
Other Operating Activities
552.01944.031,5492,270-207.944,898
Change in Accounts Receivable
4,597631.55-4,071-111.42-381.62-1,261
Change in Inventory
1,452523.9-1,623-1,920-2,769270.5
Change in Accounts Payable
-407.65-469.53-410.48-164.121,0201,173
Change in Other Net Operating Assets
1,269-3,186-2,559-193.42-3,375181.78
Operating Cash Flow
10,9531,886-3,0085,265-78.21-1,675
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-910.37-861.26-2,229-1,893-1,233-1,157
Sale (Purchase) of Intangibles
-31.85-32.46-0.7-1.52-66.23-10.71
Investment in Securities
979.26-3,146-4,023-3.18
Other Investing Activities
60.7550.75540.7455-331
Investing Cash Flow
97.79-842.971,457-5,862-1,332-1,099

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-2,0003,000-4,0004,000
Long-Term Debt Issued
--10,000--10,000
Total Debt Issued
2,0002,00013,000-4,00014,000
Short-Term Debt Repaid
----4,000-4,000-2,000
Long-Term Debt Repaid
--672.39-10,620-465.7-474.25-10,465
Total Debt Repaid
-634.03-672.39-10,620-4,466-4,474-12,465
Net Debt Issued (Repaid)
1,3661,3282,380-4,466-474.251,535
Other Financing Activities
-0-0-0--8.94-0
Financing Cash Flow
1,3661,3282,380-4,466-483.191,535

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
47.4838.05138.15-91.7-198.351.74
Net Cash Flow
12,4642,408966.43-5,155-2,092-1,237

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
10,0421,025-5,2373,372-1,311-2,831
Free Cash Flow Growth
------
Free Cash Flow Margin
19.56%1.97%-9.78%6.43%-2.62%-7.00%
Free Cash Flow Per Share
861.3087.87-449.20289.20-146.00-332.16
Levered Free Cash Flow
8,938-5.64-7,405-524.76-2,4591,277
Unlevered Free Cash Flow
9,299355.16-7,129-248.19-1,7571,984

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
625.2570.07427.49442.51491.88457.9
Cash Income Tax Paid
213.19188.6811.534.3631.28165.54
Change in Working Capital
6,992-2,500-8,663-2,389-5,506364.94